Machine-vision Image Guidance System Receives HSA Approval in Singapore Reports 7D Surgical

Achieves First Unit Sale in Southeast Asia

Machine-vision Image Guidance System (MvIGS) for spinal navigation by  7D Surgical has received approval from the Health Sciences Authority (HSA) in Singapore. The news was announced today,

In addition, 7D Surgical has already completed its first system sale through its distribution partnership with Transmedic, a premier medical technology, sales, and distribution company serving hospitals, clinics, and health centers in Southeast Asia.

“We are incredibly thrilled to bring our 7D technology to market in Singapore,” said Beau Standish, Chief Executive Officer of 7D Surgical. “We have already delivered this novel technology to the USA, Canada, Australia, New Zealand, and the Caribbean and are now excited to offer our innovations in the Asian market. Our machine vision surgical innovations improve patient outcomes by reducing surgical risk, improve implant accuracy, increase surgical efficiencies, while eliminating navigation-based intraoperative radiation. Expansion into Asia has been a strategic priority to share our innovations with the global healthcare community.”

The 7D Surgical Machine-vision Image Guidance System is the only approved image guidance system that utilizes a novel and proprietary camera-based technology, coupled with machine-vision algorithms to eliminate the long-standing frustrations with legacy surgical navigational platforms. The speed, accuracy, and efficiency of the MvIGS System, combined with a fundamentally streamlined surgical workflow provides significant economic value and harnesses the true potential of image guidance – all while enabling a safe, radiation-free surgical environment.

Associate Professor Kevin Lim, Chairman of Orthopaedic Surgery at KK Women’s and Children’s Hospital in Singapore, stated, “As a paediatric spine surgeon, the 7D system allows me to safely and accurately navigate pedicle screws at any level for any type of case, without disruption to my workflow. It is particularly paramount in some of my more complex cases, and I am proud to be able to offer my patients the very latest in spine surgery while eliminating unnecessary radiation in the operating room.”

“We are very pleased to be partnered with 7D Surgical and representing the technology in Singapore and eventually all of Southeast Asia,” said Mr. Teo Kee Meng, Managing Director at Transmedic. “We are excited by 7D Surgical’s strong innovation pipeline and believe in their cost-effective, fast, and radiation-free solution for spinal image guidance to the hospitals, clinicians, and patients that we support.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”